Geographic Atrophy

Catch up on recent advancements in retina care, including new therapies for age-related macular degeneration and macular telangiectasia, enhancing patient outcomes.

Dr. Nimesh A. Patel reveals key findings on pegcetacoplan and anti-VEGF treatments for geographic atrophy and neovascular AMD at ASRS 2025.

Jay Chhablani, MD, presented the phase 1/2 clinical trial data for OCU410, at the 2025 annual meeting of the American Society of Retina Specialists.

Vonaprument has received fast track designation from the US Food and Drug Administration.

SAR446597 is a one-time intravitreal gene therapy treatment for the treatment of geographic atrophy

Sanofi's SAR446597 receives FDA fast track designation, offering a promising one-time gene therapy for geographic atrophy and reducing treatment frequency.

Preliminary results of PST-611-CT1 are anticipated early 2026, subject to patient recruitment.

New findings reveal RG6501 cell therapy shows promising long-term visual improvements for geographic atrophy patients

A look at current therapies, clinical trial results, patient education, and emerging options for managing this progressive retinal disease.

Assistive devices empower patients with central vision loss to regain independence, enhancing daily activities and reducing reliance on low vision centers.

The trial treated 9 patients in 3 sequential, ascending dose-level (DL) cohorts.

A study reveals attrition rates in patients with geographic atrophy on complement inhibitor therapies, highlighting the need for improved treatment adherence strategies.

Discover how ellipsoid zone integrity predicts geographic atrophy growth rates in recent clinical trials, enhancing future treatment strategies.

Two FDA-approved geographic atrophy treatments show significant patient dropout, with 45% discontinuation by 18 months, driven by baseline vision, CNV, and lack of immediate visual improvement.

Vakharia insights from the ARCHER trial on geographic atrophy treatment for dry AMD, highlighting promising results and future directions in ophthalmology.

New analysis reveals the ellipsoidal zone's role in predicting geographic atrophy progression, enabling timely interventions to protect photoreceptors.

Join global experts at the 2025 International SPECTRALIS Symposium in Heidelberg, exploring innovations in ophthalmology and space-related ocular health.

The results of an investigation into iRORA identified a wide spectrum of fundus autofluorescence patterns that corresponded with iRORA lesions and that those patterns were associated with conversion to cRORA over time.